Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment
Completed
Horizon Pharma Ireland, Ltd., Dublin Ireland
Phase 3
2007-03-01
The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of
development of ibuprofen-associated ulcers in patients who require long-term daily use of
ibuprofen.
Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers
Completed
Horizon Pharma Ireland, Ltd., Dublin Ireland
Phase 3
2007-03-01
The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of
development of ibuprofen-associated ulcers in patients who require long-term daily use of
ibuprofen.
Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
Completed
Horizon Pharma Ireland, Ltd., Dublin Ireland
Phase 3
2007-09-01
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
Completed
Horizon Pharma Ireland, Ltd., Dublin Ireland
Phase 3
2009-09-01
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a
fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients
that require long-term NSAID treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
